AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06410274 — intervention group
Intervention type: DEVICE
Intervention: Transcranial Doppler ultrasonography (TCD)
Description: TCD will be used to measure cerebral blood velocity (CBv) in the middle and posterior cerebral arteries (MCA and PCA). Following confirmation of a suitable TCD window, participants will undergo a ten-minute rest period in the supine or semi-supine position. Continuous measurements of CBv, blood pressure (BP), heart rate, and end-tidal carbon dioxide will be recorded. Baseline BP will be measured using an automated BP device prior to each recording to allow calibration of the files offline for analysis. This will occur at the first visit and at follow-up, 4-7 days post-onset of intracerebral haemorrhage.
Study NCT06417424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gastrointestinal external stimulation
Description: We used the device Gastrointestinal multifunctional therapeutic instrument. The positive pole was placed 1 to 2cm above the umbilicus, and the negative pole was placed 4 to 10 cm to the right of the midpoint between the xiphoid process and the umbilicus.
Study NCT05378191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COMIRNATY
Description: One dose of COMIRNATY
Study NCT06185725 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified Perichondral Approach Thoracoabdominal Nerve Block
Description: M-TAPA block will be performed to Group M-TAPA at the end of the surgery, using US (Vivid Q) while the patient is in the supine position After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed in the sagittal plane where the midclavicular line intersects with the costal cartilage corresponding to the costochondral angle. Using the In Plane technique, the probe is gently pushed to visualize the lower part of the costochondral angle at the central level, advancing the block needle in the caudal-cranio direction, 5 ml of saline will be injected into the layer between the transverse abdominal muscle and the lower plane of the costal cartilage, and the block location will be confirmed. After the block location is confirmed, a total of 20 ml + 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
Study NCT06185725 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominal Plane Block
Description: TAP block will be performed to Group TAP at the end of the surgery, using US (Vivid Q) while the patient is in the supine position. After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. USG will be placed transversely on the mid-axillary line between the iliac crest and subcostal planes. Using the In Plane technique, the block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline. The block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline.and than 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
Study NCT05050331 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: MET involves patient-generated muscle contractions 10-20% maximum voluntary contraction from a specific position and direction, resisted by the therapist to facilitate muscle relaxation and lengthening
Study NCT05050331 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trigger Point Release
Description: Trigger point release involved applying 90 seconds of sustained thumb pressure to the trigger point, repeated three times with 30-second relaxation intervals, followed by three caudal-to-cranial longitudinal strokes along the taut band.
Study NCT05050331 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-Stretching of Calf and Plantar Fascia
Description: Participants performed a self-stretching program, comprising 5 repetitions of 20 seconds of stretching and 20 seconds of relaxation, twice daily
Study NCT04211753 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (schema therapy)
Description: weekly group psychotherapy and bimonthly individual psychotherapy
Study NCT04211753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual (schema therapy)
Description: weekly group psychotherapy and bimonthly individual psychotherapy
Study NCT04211753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile app
Description: Medical device for crisis intervention
Study NCT06463808 — intervention group
Intervention type: DRUG
Intervention: Recombinant Human Brain Natriuretic Peptide
Description: we divide our subjects into two groups;one is required to take recombinant human brain natriuretic peptide,the other is not required to take recombinant human brain natriuretic peptide
Study NCT06306807 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program including active cervical range of motion, strengthening, and posture correction exercises and ergonomic modifications
Description: Active cervical range of motion exercise program consists of the general range of movement for flexors, extensors, both sides flexors, and rotator neck muscles. Participants were instructed to perform exercises in a sitting position, but they were allowed to perform exercises in supine and prone lying if they had problems with sitting position. Strengthening exercises were planned for weak, lengthened, inhibited muscles e.g. Longus colli, and longus capitis. Chin tucks, chin tucks against gravity, and chin nod exercises were selected. Ergonomic modifications while using a smartphone were taught such as taking breaks and changing positions frequently while using a smartphone, avoiding cradling the phone between your ear and shoulder, choosing a smartphone that fits your hands properly, holding the smartphone near chest level rather than waist level, and using features including predictive text or auto-complete tools
Study NCT06306807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program including active cervical range of motion, strengthening, and posture correction exercises and ergonomic modifications
Description: Active cervical range of motion exercise program consists of the general range of movement for flexors, extensors, both sides flexors, and rotator neck muscles. Participants were instructed to perform exercises in a sitting position, but they were allowed to perform exercises in supine and prone lying if they had problems with sitting position. Strengthening exercises were planned for weak, lengthened, inhibited muscles e.g. Longus colli, and longus capitis. Chin tucks, chin tucks against gravity, and chin nod exercises were selected. Ergonomic modifications while using a smartphone were taught such as taking breaks and changing positions frequently while using a smartphone, avoiding cradling the phone between your ear and shoulder, choosing a smartphone that fits your hands properly, holding the smartphone near chest level rather than waist level, and using features including predictive text or auto-complete tools
Study NCT06306807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF exercise program
Description: The contract-relax technique for the neck extension pattern and the replication technique for the scapular posterior elevation pattern were used.
Study NCT04765683 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: Survey of views on outpatient consultation format
Study NCT05220436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DISCOVER workshop programme
Description: See arm description. The manualised group workshop day is informed by Cognitive Behaviour Therapy and Acceptance \& Commitment Therapy principles.
Study NCT05180188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: In the 8-week training period, participants will have three training sessions with a duration of 30 minutes at 70% of VO2peak per week.
Study NCT05196568 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasting mimicking diet
Description: Women will be given three administrations of fasting mimicking diet once a month
Study NCT05773144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Moderate- to vigorous-intensity aerobic exercise
Study NCT05773144 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Progressive stretching
Description: Static stretching of eight major muscle groups
Study NCT05494385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Preoperative Gabapentin/Postoperative Placebo
Description: Postoperatively, this group will receive scheduled acetaminophen and ibuprofen every 6 hours, in addition to placebo every 12 hours. The placebo is encapsulated to appear identical to the active drug. This group will have oxycodone 5 mg every 6 hours as needed for pain.
Study NCT05494385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Gabapentin/Postoperative Gabapentin
Description: Postoperatively, this group will receive scheduled acetaminophen and ibuprofen every 6 hours, in addition to gabapentin every 12 hours. The gabapentin is encapsulated to appear identical to the placebo. This group will have oxycodone 5 mg every 6 hours as needed for pain.
Study NCT04967391 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumescence During STSG Harvest
Description: Tumescence injections performed prior to STSG harvest
Study NCT06117618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse SIRS alert
Description: An electronic alert will display when a nurse opens the patient chart of a patient who meets SIRS criteria.
Study NCT06117618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prescribing clinician SIRS alert
Description: An electronic alert will display when a prescribing clinician opens the patient chart of a patient who meets SIRS criteria.
Study NCT04792645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill that contains no medicine
Study NCT04792645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Cognition-enhancing medication
Study NCT05398172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MorpheusV Applicator
Description: Eligible subjects will receive 3 treatments 4 weeks apart with the MorpheusV Applicator according to the study protocol
Study NCT06242574 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Each group will have to complete a questionnaire online, taking about 30 minutes.
Study NCT05992831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated iTBS
Description: The investigators will treat participants with accelerated intermittent theta burst stimulation. iTBS will be delivered via a MagVenture MagPro TMS System with a Cool-B65 coil, targeting to direct the stimulation to the left dorsolateral prefrontal cortex (l-dlPFC). The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold. Total treatment time will be controlled; all participants will perceive receiving active treatment for 10 3-min sessions with 10-15 min inter-session intervals, resulting in a 3-hour treatment day. At pre-treatment, a focal electrical sham will be individually titrated to participant tolerability. Participants then receive an individualized level of sham stimulation throughout treatment, to bolster the blind. Participants will be told that they will be receiving different doses throughout the treatment day, again to maintain the integrity of the blind.
Study NCT05992831 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: To achieve adequate blinding, participants will go through the same number of sessions per day irrespective of the active and/or sham dose-step combination to which they are assigned. Sham sessions will be assigned in random order over the 10 sessions. The sequence of active and/or sham sessions for each treatment day is assigned a random code that is entered into the TMS system by the coordinator to maintain the integrity of the blind.
Study NCT05992831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Comparator
Description: To achieve adequate blinding, participants will go through the same number of sessions per day irrespective of the active and/or sham dose-step combination to which they are assigned. Sham sessions will be assigned in random order over the 10 sessions. The sequence of active and/or sham sessions for each treatment day is assigned a random code that is entered into the TMS system by the coordinator to maintain the integrity of the blind.
Study NCT05803252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focused Acceptance and Commitment Therapy
Description: FACT aims to increase one's psychological flexibility so that one will not generate feelings of distress and suffering when confronted with painful life situations. The intervention of this study will follow the FACT principles laid out by Strosahl, Robinson and Gustavsson to increase parents' psychological flexibility. Three core processes influence one's psychological flexibility: awareness, openness, and engagement.~The key objectives of each core process are:~1. Awareness: Able to experience the present moment, able to take perspective on self~2. Openness: Able to detach distressing private experiences and associated rules, able to take a non-judgemental, accepting stance towards painful material~3. Engagement: Exhibits strong connection with values, able to sustain values-consistent action
Study NCT05803252 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control
Description: The waitlist control group participants will commence their FACT intervention immediately after they complete their follow-up assessment.
Study NCT05701189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efgartigimod Alfa-Fcab
Description: Efgartigimod is an anti-neonatal Fc receptor (FcRn) immunoglobulin G1 Fc fragment. The FcRn plans a critical role in extending the half-life of IgGs by rescuing them from lysosomal degradation. Antibodies that bind and subsequently block the FcRn with high affinity result in IgGs being degraded more rapidly instead of salvaged. This approach has been shown to be beneficial in the antibody-mediated disorder myasthenia gravis.
Study NCT05701189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Immunoglobulin (IVIg)
Description: IVIg is the standard-of-care treatment for GBS.
Study NCT04764799 — intervention group
Intervention type: PROCEDURE
Intervention: Rapid sequence induction
Description: Rapid sequence induction starts with the administration of rapid acting intravenous narcotics, opioids and neuromuscular blockage and avoids whenever possible positive-pressure ventilation after induction of anesthesia.
Study NCT06577610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback from colonoscopy monitoring program
Description: Adenoma detection rate feedback from colonoscopy monitoring programs
Study NCT05759026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accompaing cares
Description: After signing the consent form, the patient will be randomised. The ones randomised in VR groups will choose their preferred environment (e.g. landscapes, animals...).~The participant will be managed during 1 care (one care in control condition (no material used), care with the VR headset, one care with the VR set and the prefered environnent of the patient) for an average of 30 minutes (including the completion of the scales and questionnaires).
Study NCT06141226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 +Anlotinib+Docetaxel
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on the surface of T cells, restoring T cell activity and enhancing immune response. It has the potential to treat various types of tumors.~Anlotinib is a multi target receptor tyrosine kinase (RTK) inhibitor. It can inhibit VEGFR1, VEGFR2, VEGFR3, c-Kit, PDGFR β Activity.~Docetaxel is a taxane based anti-tumor drug.
Study NCT06141226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQB2450 +Androtinib Placebo+Docetaxel
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on the surface of T cells, restoring T cell activity and enhancing immune response. It has the potential to treat various types of tumors.~Androtinib Placebo Docetaxel is a taxane based anti-tumor drug.
Study NCT05743335 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCXH-221
Description: Participants will be randomized to either placebo or JCXH-221 for Phase 1. For Phase 2, participants will either be randomized to JCXH-221 or a FDA approved Active comparator.
Study NCT05743335 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized in Phase 1 to either JCXH-221 or placebo
Study NCT04701762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope videolaryngoscope (Verathon, Bothell, Washington 98011)
Description: After confirming adequate muscle relaxation, initial laryngoscopy will be performed using GlideScope videolaryngoscope with an appropriately sized blade (usually size 3 or 4). The GlideScope (Verathon, Bothell, Washington 98011) is an FDA-cleared commercially available portable videolaryngoscope.
Study NCT04701762 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscopy
Description: After confirming adequate muscle relaxation, initial laryngoscopy will be performed using direct laryngoscopy with an appropriately sized Macintosh or Miller blade (usually size 3 or 4);
Study NCT06500338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: free-fall
Description: The aircraft will fly in parabolas that initially produce increased gravity (1.8-G, hypergravity), followed by \~20-50 second periods of partial gravity or weightlessness. Flights which produce partial gravity (0.25-, 0.50-, and 0.75-gravity) generally will consist of 31 parabolas (at least 10 parabolas at each gravity level), and flights that produce weightlessness generally will consist of 16 parabolas.
Study NCT05180227 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DS8R
Description: transcutaneous stimulation of the spinal cord.
Study NCT05180227 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Orthostatic tilt
Description: perform an orthostatic tilt without and with stimulation.
Study NCT05180227 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Orthostatic tilt
Description: perform an orthostatic tilt without and with stimulation.
Study NCT06651944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invisalign® System with mandibular advancement featuring occlusal blocks
Description: Class II correction using the Invisalign® System with mandibular advancement featuring occlusal blocks
Study NCT06652932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low temperature (16°C) group
Description: The exposure group will be exposed to low temperature (16°C) in a chamber for about 2 hours, resting during the whole periods.
Study NCT06652932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate temperature (22°C) group
Description: The exposure group will be exposed to thermoneutral temperature (22°C) in a chamber for about 2 hours, resting during the whole periods.
Study NCT06654869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lauhgter yoga
Description: include laughter yoga effects on cancer patients' symptom management
Study NCT06655311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enlicitide Chloride
Description: Oral administration
Study NCT06655311 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study NCT04789070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus is a currently licensed drug primarily used for immunosuppression post-kidney transplantation to prevent organ rejection. Sirolimus was initially considered as a treatment in IBM for its immunosuppressive action and beneficial effects in an experimental myositis mouse model.(11) Transfer of effector T cells from affected to healthy animals resulted in myositis, but the presence of Treg cells were protective against development of myositis. As Sirolimus, which acts to deplete effector T cells but preserving the Treg cells, was effective in this mouse model of myositis, it was therefore postulated that it may also be effective in IBM, not only for its effects on effector T cells and Treg cells, but also for its additional effects on protein degradation.
Study NCT04789070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06586034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impacto (Mobile App)
Description: This is the mobile app to be developed and evaluated in this project. It is designed for both English and Spanish languages and is culturally tailored for Hispanic/Latino/Latinx individuals who smoke. Impacto will be developed for both iOS and Android platforms. The mobile app aims to aid smoking cessation by targeting elevated anxiety sensitivity.
Study NCT06593119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine management of Hypertension
Description: TM-HTN intervention includes tailored and frequent self-management support, home blood pressure monitoring, pharmacotherapy, and as-needed assistance for health-related social needs provided by pharmacists, nurses, community health workers, and social workers. This will be compared with usual care